Talphera, Inc. (NASDAQ:TLPH) Short Interest Up 191.0% in October

Talphera, Inc. (NASDAQ:TLPH) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 99,800 shares, a growth of 191.0% from the October 15th total of 34,300 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average trading volume of 90,600 shares, the days-to-cover ratio is presently 1.1 days.

Talphera Stock Performance

Shares of Talphera stock traded up $0.04 on Friday, hitting $0.70. The company’s stock had a trading volume of 58,917 shares, compared to its average volume of 90,934. Talphera has a 1 year low of $0.46 and a 1 year high of $1.61. The firm has a fifty day moving average price of $0.89 and a 200-day moving average price of $0.94. The company has a market capitalization of $11.86 million, a price-to-earnings ratio of -1.01 and a beta of 0.31.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. As a group, analysts forecast that Talphera will post -0.73 EPS for the current year.

Institutional Investors Weigh In On Talphera

Large investors have recently bought and sold shares of the company. Turtle Creek Wealth Advisors LLC purchased a new stake in Talphera during the 2nd quarter worth approximately $64,000. Rosalind Advisors Inc. purchased a new stake in shares of Talphera in the third quarter valued at approximately $650,000. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Talphera in the second quarter valued at approximately $1,773,000. 37.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Maxim Group raised Talphera to a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Talphera in a research report on Friday, August 16th.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.